Venter WDF, et al. - Researchers collected and assessed data on the use of dolutegravir (DTG) and tenofovir alafenamide fumarate (TAF) in low- and middle-income countries. They compared a triple-therapy combination of emtricitabine (FTC) and DTG plus either one of two tenofovir prodrugs—TAF (TAF-based group) or tenofovir disoproxil fumarate (TDF) (TDF-based group)—against the local standard-of-care regimen of TDF–FTC–efavirenz (standard-care group). A total of 1,053 patients underwent randomization from February 2017 through May 2018. Black patients comprised more than 99% of the sample, and 59% of the patients were female. Outcomes revealed noninferior efficacy of treatment with DTG combined with either of the two tenofovir prodrugs (TAF and TDF) vs the standard-care regimen. Weight gain was significantly higher with the DTG-containing regimens, particularly in combination with TAF, than with the standard-care regimen.